<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04634890</url>
  </required_header>
  <id_info>
    <org_study_id>R-I- 002/469/2014</org_study_id>
    <nct_id>NCT04634890</nct_id>
  </id_info>
  <brief_title>Bialystok Exercise Study in Diabetes</brief_title>
  <acronym>BESD</acronym>
  <official_title>Bialystok Exercise Study in Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Bialystok</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Copenhagen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University of Bialystok</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The &quot;Bialystok Exercise Study in Diabetes&quot; (BESD), is an exercise intervention study,&#xD;
      conducted by the Department of Endocrinology, Diabetology and Internal Medicine and Clinical&#xD;
      Research Centre of the Medical University of Bialystok. In the project, sedentary males at&#xD;
      different stages of dysglycemia living in the city of Bialystok participate in three months&#xD;
      of an exercise intervention consisting of supervised training sessions at a local fitness&#xD;
      centre. The aim of the study is to assess the effectiveness of the exercise intervention in&#xD;
      patients at different stages of dysglycemia progression, including type 2 diabetes and&#xD;
      prediabetes and compare the response between groups.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 11, 2016</start_date>
  <completion_date type="Anticipated">December 20, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 20, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HbA1c</measure>
    <time_frame>Three months</time_frame>
    <description>Haemoglobin A1c measured by the high-performance liquid chromatography (HPLC) method</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fasting glucose</measure>
    <time_frame>Three months</time_frame>
    <description>Fasting glucose concentration measured in plasma using the colorimetric method</description>
  </primary_outcome>
  <primary_outcome>
    <measure>2-hour glucose</measure>
    <time_frame>Three months</time_frame>
    <description>Glucose concentration at 2-hour of the oral glucose tolerance test, measured in plasma using the colorimetric method</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fasting insulin</measure>
    <time_frame>Three months</time_frame>
    <description>Fasting insulin concentration measured in plasma using the immunoradiometric assay (IRMA)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lean body mass</measure>
    <time_frame>Three months</time_frame>
    <description>Total lean body mass measured using the whole-body dual-energy X-ray absorptiometry (DXA)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fat mass</measure>
    <time_frame>Three months</time_frame>
    <description>Total body fat mass measured using the whole-body dual-energy X-ray absorptiometry (DXA)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visceral Adipose Tissue mass</measure>
    <time_frame>Three months</time_frame>
    <description>Visceral adipose tissue mass measured using the whole-body dual-energy X-ray absorptiometry (DXA)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Weight</measure>
    <time_frame>Three months</time_frame>
    <description>Total body weight measured using standardized scale</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HOMA-IR</measure>
    <time_frame>Three months</time_frame>
    <description>Homeostatic model assessment for insulin resistance</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HOMA-beta</measure>
    <time_frame>Three months</time_frame>
    <description>Homeostatic model assessment of beta cell function</description>
  </primary_outcome>
  <primary_outcome>
    <measure>VO2max</measure>
    <time_frame>Three months</time_frame>
    <description>Maximal oxygen consumption measured during cardio-pulmonary exercise test on treadmill</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Triglycerides (TG)</measure>
    <time_frame>Three months</time_frame>
    <description>Serum triglycerides concentration measured using colorimetric method</description>
  </primary_outcome>
  <primary_outcome>
    <measure>High-density lipoprotein cholesterol (HDL)</measure>
    <time_frame>Three months</time_frame>
    <description>Serum high-density lipoprotein cholesterol (HDL) concentration measured using colorimetric method</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Low-density lipoprotein cholesterol (LDL)</measure>
    <time_frame>Three months</time_frame>
    <description>Serum low-density lipoprotein cholesterol (LDL) concentration measured using colorimetric method</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total cholesterol</measure>
    <time_frame>Three months</time_frame>
    <description>Serum total cholesterol concentration measured using colorimetric method</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma metabolome</measure>
    <time_frame>Three months</time_frame>
    <description>Changes in plasma metabolites concentrations measured using untargeted metabolomics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Skeletal muscle metabolome</measure>
    <time_frame>Three months</time_frame>
    <description>Changes in skeletal muscle metabolites concentrations measured using untargeted metabolomics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subcutaneous adipose tissue metabolome</measure>
    <time_frame>Three months</time_frame>
    <description>Changes in subcutaneous adipose tissue metabolites concentrations measured using untargeted metabolomics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Skeletal muscle transcriptome</measure>
    <time_frame>Three months</time_frame>
    <description>Changes in skeletal muscle gene and smallRNA expressions measured using untargeted transcriptomics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subcutaneous adipose tissue transcriptome</measure>
    <time_frame>Three months</time_frame>
    <description>Changes in subcutaneous adipose tissue gene and smallRNA expressions measured using untargeted transcriptomics</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Type 2 Diabetes</condition>
  <condition>PreDiabetes</condition>
  <condition>Overweight</condition>
  <condition>Obesity</condition>
  <condition>Dyslipidemias</condition>
  <arm_group>
    <arm_group_label>Type 2 Diabetes</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Subjects with type 2 diabetes, diagnosed within the last 3-5 years, treated with metformin only as an anti-diabetic drug</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prediabetes</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Subjects with prediabetes, defined as impaired fasting glucose or/and impaired glucose tolerance</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normoglycemia</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Subjects with normal fasting glucose and normal glucose tolerance</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Exercise intervention</intervention_name>
    <description>Supervised exercise intervention composed of mixed aerobic and strength activities, with the frequency of 3 sessions per week for 12 weeks, for a total number of trainings of 36.</description>
    <arm_group_label>Normoglycemia</arm_group_label>
    <arm_group_label>Prediabetes</arm_group_label>
    <arm_group_label>Type 2 Diabetes</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age: 35-65 years old&#xD;
&#xD;
          -  BMI: 25-35 kg/m2&#xD;
&#xD;
          -  Male gender&#xD;
&#xD;
          -  Ability of performing exercise trainings&#xD;
&#xD;
          -  Sedentary lifestyle&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Smoking&#xD;
&#xD;
          -  Drug or alcohol addiction&#xD;
&#xD;
          -  Any chronic disease (exceptions: hypertension, obesity with BMI â‰¤ 35 kg/m2, type 2&#xD;
             diabetes)&#xD;
&#xD;
          -  Any chronic medications (exceptions: angiotensin-converting-enzyme inhibitors for&#xD;
             hypertension and metformin in type 2 diabetics)&#xD;
&#xD;
          -  Highly active lifestyle&#xD;
&#xD;
          -  Medical contraindications to participate in planned exercise sessions&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Clinical Research Centre, Medical University of Bialystok</name>
      <address>
        <city>Bialystok</city>
        <state>Podlaskie</state>
        <zip>15-276</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lukasz Szczerbinski, MD, PhD</last_name>
      <phone>+48 85 831 81 50</phone>
      <email>lukasz.szczerbinski@umb.edu.pl</email>
    </contact>
    <investigator>
      <last_name>Adam Kretowski, Prof., MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lukasz Szczerbinski, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 12, 2020</study_first_submitted>
  <study_first_submitted_qc>November 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 18, 2020</study_first_posted>
  <last_update_submitted>November 12, 2020</last_update_submitted>
  <last_update_submitted_qc>November 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>exercise intervention</keyword>
  <keyword>type 2 diabetes prevention</keyword>
  <keyword>type 2 diabetes treatment</keyword>
  <keyword>prediabetes</keyword>
  <keyword>behavioural intervention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Dyslipidemias</mesh_term>
    <mesh_term>Prediabetic State</mesh_term>
    <mesh_term>Glucose Intolerance</mesh_term>
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

